Thera-SAbDab

RITUXIMAB

>   Structural Summary
TherapeuticRituximab
TargetMS4A1
Heavy ChainQVQLQQPGAELVKPGASVKMSCKASGYTFTSYNMHWVKQTPGRGLEWIGAIYPGNGDTSYNQKFKGKATLTADKSSSTAYMQLSSLTSEDSAVYYCARSTYYGGDWYFNVWGAGTTVTVSA
Light ChainQIVLSQSPAILSASPGEKVTMTCRASSSVSYIHWFQQKPGSSPKPWIYATSNLASGVPVRFSGSGSGTSYSLTISRVEAEDAATYYCQQWTSNPPTFGGGTKLEIK
100% seqID Fv Structure2osl [Fvs: AB, HL]
99% seqID Fv Structure4kaq [Fvs: HL]
95-98% seqID Fv StructureNone
>   Alignments

Non-identical sequences have been numbered using the Chothia scheme and aligned to Rituximab.
CDR positions are indicated in blue. Mismatching positions are highlighted in orange.

Sequence identity: 98.68%

Heavy chain

Position 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 52A 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 82A 82B 82C 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 100A 100B 100C 100D 101 102 103 104 105 106 107 108 109 110 111 112 113
rituximab Q V Q L Q Q P G A E L V K P G A S V K M S C K A S G Y T F T S Y N M H W V K Q T P G R G L E W I G A I Y P G N G D T S Y N Q K F K G K A T L T A D K S S S T A Y M Q L S S L T S E D S A V Y Y C A R S T Y Y G G D W Y F N V W G A G T T V T V S A
4kaq E V Q L Q Q P G A E L V K P G A S V K M S C K A S G Y T F T S Y N M H W V K Q T P G R G L E W I G A I Y P G N G D T S Y N Q K F K G K A T L T A D K S S S T A Y M Q L S S L T S E D S A V Y Y C A R S T Y Y G G D W Y F N V W G A G T T V T V S A

Light chain

Position 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 101 102 103 104 105 106 107
rituximab Q I V L S Q S P A I L S A S P G E K V T M T C R A S S S V S - Y I H W F Q Q K P G S S P K P W I Y A T S N L A S G V P V R F S G S G S G T S Y S L T I S R V E A E D A A T Y Y C Q Q W T S N P P T F G G G T K L E I K
4kaq Q I V L S Q S P A I L S A S P G E K V T M T C R A S S S V - S Y I H W F Q Q K P G S S P K P W I Y A T S N L A S G V P V R F S G S G S G T S Y S L T I S R V E A E D A A T Y Y C Q Q W T S N P P T F G G G T K L E I K
>   Metadata
FormatWhole mAb
IsotypeG1
Highest Clinical Trial (June '19)Approved
Estimated Status (June '19)Active
Recorded Developmental Technologyna
INN Year Proposed1997
INN Year Recommended1998
Companies InvolvedBiogen, Biogen Idec, Cedars-Sinai Medical Center, Chugai Pharmaceutical, Genentech, Hackensack University Medical Center, Hoosier Cancer Research Network, Janssen Research & Development, M. D. Anderson Cancer Center, Mayo Clinic, Nagoya University, Oregon Health & Science University, Roche, SCRI Development Innovations, Takeda Oncology, University of Gottingen, University of Texas M. D. Anderson Cancer Center, University of Tours, Zenyaku Kogyo
Conditions ApprovedChronic lymphocytic leukaemia, Diffuse large B cell lymphoma, Follicular lymphoma, Idiopathic thrombocytopenic purpura, Lymphoproliferative disorders, Microscopic polyangiitis, Nephrotic syndrome, Non-Hodgkin's lymphoma, Pemphigus vulgaris, Rheumatoid arthritis, Wegener's granulomatosis
Conditions ActiveMantle-cell lymphoma, Transplant rejection, Neuromyelitis optica, B-cell lymphoma, Chronic inflammatory demyelinating polyradiculoneuropathy, Glomerulonephritis, Precursor cell lymphoblastic leukaemia-lymphoma, Renal transplant rejection
Conditions DiscontinuedMultiple sclerosis, Ocular inflammation, Primary biliary cirrhosis, Scleritis, Sjogren's syndrome, Ulcerative colitis, Dermatomyositis, Graft-versus-host disease, Lupus nephritis, Systemic lupus erythematosus
Notes

SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]

Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]